知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

33 records (took 0.017 seconds)

    CD1d and TCR-NKT Cells
    3.
    发明申请
    CD1d and TCR-NKT Cells 审中-公开

    公开(公告)号：US20200270574A1

    公开(公告)日：2020-08-27

    申请号：US16649082

    申请日：2018-09-28

    Applicant: NantCell, Inc.

    Inventor： Patrick Soon-Shiong ,  Kayvan Niazi

    IPC: C12N5/0783 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K14/725 ,  C07K14/705 ,  C12N9/22

    Abstract: Compositions, methods and uses of genetically modified NKT cells to induce an NKT cell immune response against tumor or to change a microenvironment of the tumor by suppressing an activity of myeloid-derived suppressor cells are presented. In some embodiments, naive NKT cells are obtained from a patient having a tumor, and are genetically engineered to include a chimeric protein, a T cell receptor, a hybrid T cell receptor replacing the endogenous T cell receptor, or one of CD40L and Fas-L. The naive or genetically modified NKT cells can be administered to a cancer patient to trigger and/or boost immune response against the tumor.

    Production and delivery tracking and sample verification of patient-specific therapeutics
    5.
    发明授权
    Production and delivery tracking and sample verification of patient-specific therapeutics 有权

    公开(公告)号：US11894109B1

    公开(公告)日：2024-02-06

    申请号：US16561773

    申请日：2019-09-05

    Applicant: NantCell, Inc.

    Inventor： Kayvan Niazi ,  Nicholas Witchey

    IPC: G16H10/40 ,  G06F16/23 ,  G01N33/58 ,  G06Q50/04 ,  G16H20/10

    CPC classification number: G16H10/40 ,  G01N33/58 ,  G06F16/2379 ,  G06Q50/04 ,  G16H20/10 ,  G06Q2220/00

    Abstract: Systems and methods for tracking biological samples are presented. In some embodiments, intrinsic and extrinsic biological sample data and/or intrinsic and extrinsic patient data are used to label a biological sample obtained at a point-of-care facility. The labeled biological sample may be sent to a processing facility, wherein the labeled biological sample undergoes analysis and/or processing into a labeled therapeutic. The labeled therapeutic is delivered back to the point-of-care facility, wherein the labeled therapeutic is tested for the presence of the additives prior to administration to a patient. Multi-factor validation is performed, including validating the identity of the patient to a container, validating the identity of the labeled biological sample/therapeutic to the container, and thus, validating the identity of the labeled therapeutic to the patient. The entire life cycle of a biological sample used to generate a personalized therapeutic is validated, and ensures that mix-ups or errors in administration are reduced or eliminated.

    Methods of Immunogenic Modulation
    8.
    发明申请
    Methods of Immunogenic Modulation 有权

    公开(公告)号：US20210223231A1

    公开(公告)日：2021-07-22

    申请号：US16076280

    申请日：2017-02-16

    Applicant: NANT HOLDINGS IP, LLC ,  NANTCELL, INC.

    Inventor： Patrick Soon-Shiong ,  Kayvan Niazi ,  Shahrooz Rabizadeh

    IPC: G01N33/50 ,  G01N33/68

    Abstract: Ex vivo determination of increased tumor immunogenicity of a tumor biopsy is used as a guide to identify immunotherapy of a tumor in a patient. Most preferably, the ex vivo tests will include exposure of biopsy samples to stress conditions to produce pretreated tumor cells that are then assayed with immune competent cells for increased activation or activity. Test conditions include exposure of the biopsy samples to immune stimulatory compositions, antibodies against neoepitopes, and/or modified cells, and an increase of immunogenicity is preferably determined by their exposure to T cells and/or NK cells.

Patent Agency Ranking